NASDAQ:MNMD • CA60255C8850
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MIND MEDICINE MINDMED INC (MNMD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-23 | Jones Trading | Initiate | Buy |
| 2025-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-13 | Needham | Initiate | Buy |
| 2025-08-04 | Oppenheimer | Reiterate | Outperform |
| 2025-08-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-07 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-28 | Evercore ISI Group | Initiate | Outperform |
| 2024-12-20 | Chardan Capital | Initiate | Buy |
| 2024-12-17 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-24 | Roth MKM | Maintains | Buy -> Buy |
| 2024-06-21 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-05-28 | Baird | Initiate | Outperform |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-15 | Leerink Partners | Initiate | Outperform |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 189.62% | N/A 249.47% | N/A 72.05% | N/A 36.98% | N/A 35.88% | N/A 33.01% | ||||||||||
| EBITDA YoY % growth | N/A | -150K | -1.22M -713.33% | -850K 30.33% | -460K 45.88% | -33.03M -7,080.43% | -91.23M -176.20% | -63.15M 30.78% | -90.704M -43.63% | -103.389M -13.99% | N/A -59.03% | N/A -16.25% | N/A 8.06% | N/A 67.06% | N/A 181.85% | N/A 836.81% | N/A 68.79% | N/A 87.67% | N/A 49.29% | |
| EBIT YoY % growth | -50K | -150K -200.00% | -1.23M -720.00% | -860K 30.08% | -470K 45.35% | -33.03M -6,927.66% | -93.85M -184.14% | -66.33M 29.32% | -93.866M -41.51% | -103.916M -10.71% | N/A -62.41% | N/A -18.85% | N/A 9.80% | N/A 50.27% | N/A 280.43% | N/A 182.17% | N/A 70.41% | N/A 51.83% | N/A 23.21% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A -106.06% | -1.92 44.64% | -2.32 -20.83% | -2.08 10.34% | N/A -1.31% | N/A 11.77% | N/A 13.32% | N/A 31.22% | N/A 193.13% | N/A 211.76% | N/A 85.90% | N/A 43.86% | N/A 46.45% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.51 -24.62% | -0.46 -71.26% | -0.46 7.86% | -0.46 40.94% | -0.46 10.83% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -43.35M -35.74% | -49.47M -53.83% | -52.02M -27.18% | -57.63M -26.19% | -63.24M -45.88% |
| EBIT Q2Q % growth | -47.654M -46.80% | -48.818M -51.80% | -50.785M -24.16% | -51.644M -13.08% | -52.267M -9.68% |
All data in USD
19 analysts have analysed MNMD and the average price target is 29.16 USD. This implies a price increase of 94.11% is expected in the next year compared to the current price of 15.02.
MIND MEDICINE MINDMED INC (MNMD) will report earnings on 2026-03-04, after the market close.
The consensus EPS estimate for the next earnings of MIND MEDICINE MINDMED INC (MNMD) is -0.51 USD and the consensus revenue estimate is 0 USD.